Why Your Women's Health Pitch Deck Needs to Be More Than a Pink Slide Deck

Picture the scene: a room full of investors, predominantly men, who have enthusiastically funded 17 enterprise SaaS tools for optimizing office snack procurement, but who furrow their brows with great concern when a women's health founder walks in.

"Is this really a big enough market?" they ask, about conditions affecting half the global population. Great stuff.

The femtech and women's health sector is one of the fastest-growing in global healthcare, and yet it remains catastrophically underfunded. It's not because the products aren't needed, but because too many pitches land in rooms where the default assumption is scepticism.

Founders in this space are brilliant, clinically rigorous, and solving some of the most consequential gaps in modern medicine. The problem isn't them. It's that the standard pitch deck — built for a funding ecosystem that wasn't designed with this sector in mind — doesn't do the work it needs to do.

The stakes are real. Global femtech investment hit $2.2B in 2024, yet it accounts for only 8.5% of total digital health funding despite women accounting for 80% of household healthcare decisions in the US alone. The gap isn't just a funding problem; it's also a communication problem. And your pitch deck is where it starts.

Why Women's Health Pitch Decks Need to Be Different

Women's health operates at the intersection of science, stigma, policy, and lived experience in a way that most other verticals simply don't. But its uniqueness means that founders have to take a different approach to creating a pitch deck.

A pitch for a diabetes management app doesn't have to spend three slides justifying that diabetes exists, is undertreated, and that patients' concerns have historically been dismissed.

A pitch for an endometriosis platform, however, often does because investors may have never heard of the condition, may not understand why diagnosis takes an average of 7.5 years (Armour et al., BJOG, 2019), and may need help connecting those clinical gaps to commercial opportunity.

Women's health pitches must do more educational groundwork than almost any other sector. It's just good strategy.

The sector also carries unique layers of complexity:

• Regulatory nuance: Reproductive health products face additional political and regulatory risk that must be addressed proactively, especially post-Dobbs in the US context

• Clinical evidence gaps: Decades of male-default research means your product may be solving a problem that has never been formally studied, which is simultaneously your pitch and your challenge

• Stigma and taboo: Conditions like vaginismus, perimenopause, or postpartum mental health require desensitized, clinical framing in investor decks without losing the human story

• Diverse audience within the category: "Women's health" covers everything from fertility (age 20–40) to menopause (40–60+) to osteoporosis (60+). Investors need to know you know the difference.

What Your Deck Must Encompass

A strong women's health pitch deck should include all the standard components (problem, solution, market, traction, team, financials), but several slides require specific treatment.

1. The Problem Slide: Lead With Clinical Evidence, Not Emotion

This is where most founders go wrong in both directions. Either they over-index on emotional storytelling (which can read as anecdotal to sceptical investors) or they present dry statistics with no human context. You need both, sequenced carefully.

Do say: "Polycystic ovary syndrome affects 1 in 10 women of reproductive age globally, yet 70% remain undiagnosed (Bozdag et al., Human Reproduction, 2016). Current diagnostic pathways take an average of 2 years and involve multiple specialists. Our platform reduces time-to-diagnosis to under 3 months."

Don't say: "Every woman knows the frustration of not being listened to by doctors. We're changing that."

The first demonstrates market failure with clinical precision and ties it directly to your solution. The second is true, resonant, and completely unfundable on its own.

2. The Market Slide: Go Beyond TAM

Femtech's total addressable market is projected to reach USD 97.25 billion by 2030, but savvy investors have seen that number before. Differentiate by showing serviceable addressable market (SAM) and serviceable obtainable market (SOM) with specificity, and layer in the underserved dimension.

Do say: "Our SAM is the 12 million women in the UK aged 45–55 actively seeking perimenopause support, of whom only 14% are currently accessing HRT or structured clinical care — representing a £2.4bn underserved opportunity."

Don't say: "The women's wellness market is worth billions and growing fast."

3. The Clinical Validation Slide: Non-Negotiable

Unlike consumer wellness, health products need evidence. Even early-stage founders should present pilot data, advisory board credentials, or peer-reviewed literature supporting the underlying clinical need. An advisory board that includes a gynaecologist, a health economist, and a patient advocate signals seriousness.

4. The Stigma & Sensitivity Slide (Yes, It's a Slide Now)

For conditions carrying social stigma (think menstrual health, sexual dysfunction, fertility, postpartum depression), address head-on how your go-to-market accounts for patient privacy, destigmatisation, and safe digital environments. Investors who haven't thought about this will be impressed. Those who have been burned by backlash in the space will be relieved.

The Do's and Don'ts at a Glance

Category	✅ Do This	❌ Not This
Opening hook	Lead with a clinical statistic and a clear market gap	"As a woman, I've personally experienced..."
Market size	Use SAM/SOM with diagnosis or treatment rates	Generic TAM figures without segmentation
Tone	Clinical, confident, evidence-based	Apologetic, over-emotive, or overly "empowerment" focused
Team slide	Highlight clinical advisors and patient community connections	All-women team without medical credibility flagged
Regulatory	Address proactively with a clear compliance roadmap	Ignore or minimize regulatory complexity
Financials	Model conservative and optimistic paths with clear assumptions	Hockey-stick curves with no clinical milestones attached
Competition	Name clinical pathways and incumbents honestly	"There's no competition in this space"

Who's In the Room, and Why It Matters

Analysis of global venture capital deployment shows that of the $289 billion invested globally in 2024:

• 2.3% went to female-only founding teams ($6.7 billion)

• 83.6% went to all-male founding teams ($241.9 billion)

  
  

That's not an excuse to change your team, but it is a reason to anticipate the questions you'll get that your male counterparts won't.

Prepare for: "Is this really a big enough market?" (It is. Have the data.) "Will men feel excluded by this product?" (Address this with clarity, not defensiveness.) "What happens if legislation changes?" (Have a contingency. Show you've thought about it.)

The goal isn't to fight bias in the room. The goal is actually to make your deck so airtight that bias has nowhere to hide.

The Founder Narrative: Where to Put It

Your personal story, if relevant, belongs in one place: the "why now, why us" section, and it should be one to two sentences maximum before pivoting back to market evidence. Founder passion is table stakes. Clinical understanding and commercial acumen are differentiators.

Do say: "After my own diagnosis journey took four years, I spent two years working with NHS gynaecologists and data scientists to build a solution that shortens that timeline, not just for people like me, but for the 1.5 million women in the UK alone with the same condition."

Don't say: "My painful personal experience inspired me to make a difference."

One of these opens a door. The other closes one.

No More Dusty Rose Color Palettes

Women's health is not a niche. Nor is it a passion project or a charity. It is one of the most structurally underserved verticals in global healthcare, with clinical evidence gaps, and decades of ignored patient data creating white space that any serious investor should be salivating over. But they won't do that unless you can show them how to see it.

Your pitch deck is your translation layer. Make it rigorous, make it human, and make it impossible to dismiss.

And for the love of all that is clinical and commercially viable, put down the dusty rose color palette.